182 related articles for article (PubMed ID: 31965618)
21. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
[TBL] [Abstract][Full Text] [Related]
22. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Erstad DJ; Sojoodi M; Taylor MS; Jordan VC; Farrar CT; Axtell AL; Rotile NJ; Jones C; Graham-O'Regan KA; Ferreira DS; Michelakos T; Kontos F; Chawla A; Li S; Ghoshal S; Chen YI; Arora G; Humblet V; Deshpande V; Qadan M; Bardeesy N; Ferrone CR; Lanuti M; Tanabe KK; Caravan P; Fuchs BC
Clin Cancer Res; 2020 Sep; 26(18):5007-5018. PubMed ID: 32611647
[TBL] [Abstract][Full Text] [Related]
23. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.
Panni RZ; Gonzalez I; Hartley CP; Williams GA; Liu J; Hawkins WG; Chatterjee D
Am J Surg Pathol; 2018 Nov; 42(11):1480-1487. PubMed ID: 30179901
[TBL] [Abstract][Full Text] [Related]
24. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
25. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade.
König AK; Gros H; Hinz U; Hank T; Kaiser J; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jan; 48(1):113-120. PubMed ID: 34344573
[TBL] [Abstract][Full Text] [Related]
26. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
27. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
28. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
[TBL] [Abstract][Full Text] [Related]
29. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
30. Measured residual tumor cellularity correlates with survival in neoadjuvant treated pancreatic ductal adenocarcinomas.
Rowan DJ; Logunova V; Oshima K
Ann Diagn Pathol; 2019 Feb; 38():93-98. PubMed ID: 30562721
[No Abstract] [Full Text] [Related]
31. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.
Saka B; Balci S; Basturk O; Bagci P; Postlewait LM; Maithel S; Knight J; El-Rayes B; Kooby D; Sarmiento J; Muraki T; Oliva I; Bandyopadhyay S; Akkas G; Goodman M; Reid MD; Krasinskas A; Everett R; Adsay V
Ann Surg Oncol; 2016 Jun; 23(6):2010-8. PubMed ID: 26832882
[TBL] [Abstract][Full Text] [Related]
33. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
34. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.
Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Bui JL; Yuan C; Qian ZR; Babic A; Da Silva A; Nowak JA; Khalaf N; Brais LK; Welch MW; Zellers CL; Ng K; Chang DT; Miksad RA; Bullock AJ; Tseng JF; Swanson RS; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Hornick JL; Ogino S; Fuchs CS; Hezel AF; Koong AC; Wolpin BM
Br J Cancer; 2017 Dec; 117(12):1874-1882. PubMed ID: 28982112
[TBL] [Abstract][Full Text] [Related]
35. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
36. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.
Das R; McGrath K; Seiser N; Smith K; Uttam S; Brand RE; Fasanella KE; Khalid A; Chennat JS; Sarkaria S; Singh H; Slivka A; Zeh HJ; Zureikat AH; Hogg ME; Lee KK; Paniccia A; Ongchin MC; Pingpank JF; Boone BA; Dasyam AK; Bahary N; Gorantla VC; Rhee JC; Thomas R; Ellsworth S; Landau MS; Ohori NP; Henn P; Shyu S; Theisen BK; Singhi AD
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):886-897. PubMed ID: 33278573
[TBL] [Abstract][Full Text] [Related]
37. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
38. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
40. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
